Disease relevance of RFTN1

• Examination of 30 frozen breast tumors supported the finding that MIG2 is overexpressed in a subset of breast cancers [1].

High impact information on RFTN1

• Disruption of the Raftlin gene in the DT40 B-cell line resulted in a marked reduction in the quantity of lipid raft components, including Lyn and ganglioside GM1, while overexpression of Raftlin increased the content of raft protein [2].
• Like the Src family kinase, Raftlin is localized exclusively in lipid rafts by fatty acylation of N-terminal Gly2 and Cys3, and is co-localized with BCR before and after BCR stimulation [2].
• The B cell-specific major raft protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction [2].
• Moreover, BCR-mediated tyrosine phosphorylation and calcium mobilization were impaired by the lack of Raftlin and actually potentiated by overexpression of Raftlin [2].
• Although all 21 normal tissues from reduction mammoplasty showed immunoreactivity for MIG2, ranging from weak (62%) to strong (24%), only half of the 34 formalin-fixed breast tumors showed immunoreactivity for MIG2 [1].

Anatomical context of RFTN1

• Using real-time reverse transcription-PCR, we found that mitogen-inducible gene 2 (MIG2) is expressed at a 17-fold higher level in TMX2-28 cells than in nonaggressive MCF-7 cells and that MIG2 mRNA levels are low in the nontumorigenic human mammary epithelial cell line, 184 [1].

Analytical, diagnostic and therapeutic context of RFTN1

• Finally, MIG2 expression was evaluated in reductive mammoplasty and breast tumor tissue [1].

References